Miryam Mebarki

1.1k total citations
19 papers, 628 citations indexed

About

Miryam Mebarki is a scholar working on Oncology, Genetics and Surgery. According to data from OpenAlex, Miryam Mebarki has authored 19 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Genetics and 5 papers in Surgery. Recurrent topics in Miryam Mebarki's work include CAR-T cell therapy research (9 papers), Mesenchymal stem cell research (8 papers) and Tissue Engineering and Regenerative Medicine (4 papers). Miryam Mebarki is often cited by papers focused on CAR-T cell therapy research (9 papers), Mesenchymal stem cell research (8 papers) and Tissue Engineering and Regenerative Medicine (4 papers). Miryam Mebarki collaborates with scholars based in France, United States and Italy. Miryam Mebarki's co-authors include Jérôme Larghero, Audrey Cras, Nathalie Chevallier, Pierre Layrolle, Grégory Jouvion, David Briand, Jean Bardon, Nicola Latronico, Aude Lafoux and Laurent Châtre and has published in prestigious journals such as Nature Communications, Blood and Acta Biomaterialia.

In The Last Decade

Miryam Mebarki

19 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miryam Mebarki France 11 193 189 146 136 118 19 628
Paula Kolar Germany 13 162 0.8× 267 1.4× 129 0.9× 260 1.9× 137 1.2× 17 1.0k
Anna Valeria Samarelli Italy 15 206 1.1× 211 1.1× 89 0.6× 137 1.0× 41 0.3× 22 642
Alfred Gugerell Austria 19 156 0.8× 285 1.5× 83 0.6× 192 1.4× 107 0.9× 42 859
Hongxiang Liu China 14 56 0.3× 109 0.6× 209 1.4× 90 0.7× 37 0.3× 40 645
A. van Dijk Netherlands 12 305 1.6× 148 0.8× 57 0.4× 308 2.3× 209 1.8× 21 759
Jens Tuischer Germany 9 193 1.0× 156 0.8× 43 0.3× 312 2.3× 168 1.4× 18 700
Daniel Toben Germany 9 131 0.7× 389 2.1× 147 1.0× 251 1.8× 143 1.2× 10 873
Paweł Łęgosz Poland 10 250 1.3× 232 1.2× 46 0.3× 334 2.5× 91 0.8× 47 805
Gunter Kerst Germany 18 222 1.2× 298 1.6× 106 0.7× 228 1.7× 115 1.0× 64 1.2k

Countries citing papers authored by Miryam Mebarki

Since Specialization
Citations

This map shows the geographic impact of Miryam Mebarki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miryam Mebarki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miryam Mebarki more than expected).

Fields of papers citing papers by Miryam Mebarki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miryam Mebarki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miryam Mebarki. The network helps show where Miryam Mebarki may publish in the future.

Co-authorship network of co-authors of Miryam Mebarki

This figure shows the co-authorship network connecting the top 25 collaborators of Miryam Mebarki. A scholar is included among the top collaborators of Miryam Mebarki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miryam Mebarki. Miryam Mebarki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Pourroy, Bertrand, et al.. (2025). The pharmaceutical circuit of Advanced Therapy Medicinal Products—guidelines of the French Society for Oncology Pharmacy. Cytotherapy. 27(8). 1023–1030. 1 indexed citations
2.
3.
Rossi, Elisa, Miryam Mebarki, Pascale Gaussem, et al.. (2024). Understanding the Angiogenic Characteristics of Clinical-Grade Mesenchymal Stromal Cells Isolated from Human Umbilical Cord. Stem Cell Reviews and Reports. 20(5). 1353–1356. 1 indexed citations
4.
Larghero, Jérôme, et al.. (2023). Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies. Blood Advances. 8(2). 337–342. 36 indexed citations
5.
6.
Cuffel, Alexis, Vincent Allain, Lionel Faivre, et al.. (2022). Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Advances. 6(15). 4657–4660. 20 indexed citations
7.
8.
Galtier, Jean, Laëtitia Vercellino, Loïc Chartier, et al.. (2022). Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells. Haematologica. 108(1). 171–180. 19 indexed citations
9.
Mebarki, Miryam, et al.. (2021). Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France. Therapies. 77(2). 185–190. 3 indexed citations
10.
Mebarki, Miryam, Guillaume Churlaud, Antoine Monsel, et al.. (2021). Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases. Stem Cell Research & Therapy. 12(1). 571–571. 26 indexed citations
11.
Mebarki, Miryam, et al.. (2021). Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products. Stem Cell Research & Therapy. 12(1). 152–152. 116 indexed citations
12.
Madelaine, Isabelle, et al.. (2021). Les médicaments de thérapie génique CAR-T cells : statuts réglementaires et circuits pharmaceutiques en Europe et en France. Bulletin du Cancer. 108(10). S162–S167. 3 indexed citations
13.
Guilbaud, Lucie, Mathilde Weber, Thomas Lilin, et al.. (2021). In utero treatment of myelomeningocele with allogenic umbilical cord-derived mesenchymal stromal cells in an ovine model. Current Research in Translational Medicine. 70(1). 103314–103314. 8 indexed citations
14.
Cartier, F, Isabelle Madelaine, Nicolas Boissel, et al.. (2020). Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers. Cytotherapy. 22(12). 792–801. 6 indexed citations
15.
Reppel, Loïc, et al.. (2020). Mesenchymal stem/stromal cell quality control: validation of mixed lymphocyte reaction assay using flow cytometry according to ICH Q2(R1). Stem Cell Research & Therapy. 11(1). 426–426. 22 indexed citations
16.
Mebarki, Miryam, Annelise Bennaceur‐Griscelli, & Laurence Bonhomme‐Faivre. (2018). Human-cell-derived organoids as a new ex vivo model for drug assays in oncology. Drug Discovery Today. 23(4). 857–863. 22 indexed citations
17.
Mebarki, Miryam, Pierre Layrolle, Séverine Battaglia, et al.. (2017). Enhanced human bone marrow mesenchymal stromal cell adhesion on scaffolds promotes cell survival and bone formation. Acta Biomaterialia. 59. 94–107. 67 indexed citations
18.
Brennan, Meadhbh Á., Audrey Renaud, Fabien Guilloton, et al.. (2017). Inferior In Vivo Osteogenesis and Superior Angiogeneis of Human Adipose-Derived Stem Cells Compared with Bone Marrow-Derived Stem Cells Cultured in Xeno-Free Conditions. Stem Cells Translational Medicine. 6(12). 2160–2172. 67 indexed citations
19.
Rocheteau, Pierre, Laurent Châtre, David Briand, et al.. (2015). Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy. Nature Communications. 6(1). 10145–10145. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paula Kolar Breakdown of academic impact, for papers by Anna Valeria Samarelli Breakdown of academic impact, for papers by Alfred Gugerell Breakdown of academic impact, for papers by Hongxiang Liu Breakdown of academic impact, for papers by A. van Dijk Breakdown of academic impact, for papers by Jens Tuischer Breakdown of academic impact, for papers by Daniel Toben Breakdown of academic impact, for papers by Paweł Łęgosz Breakdown of academic impact, for papers by Gunter Kerst
Rankless by CCL
2026